220 related articles for article (PubMed ID: 17227801)
1. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
[TBL] [Abstract][Full Text] [Related]
3. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
[TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
6. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
Grey A; Bolland MJ; Wattie D; Horne A; Gamble G; Reid IR
J Clin Endocrinol Metab; 2009 Feb; 94(2):538-44. PubMed ID: 19050050
[TBL] [Abstract][Full Text] [Related]
7. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
Grey A; Bolland M; Wattie D; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2010 Oct; 25(10):2251-5. PubMed ID: 20499349
[TBL] [Abstract][Full Text] [Related]
8. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
[TBL] [Abstract][Full Text] [Related]
9. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
[TBL] [Abstract][Full Text] [Related]
10. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
[TBL] [Abstract][Full Text] [Related]
11. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
[TBL] [Abstract][Full Text] [Related]
12. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Shane E; Cohen A; Stein EM; McMahon DJ; Zhang C; Young P; Pandit K; Staron RB; Verna EC; Brown R; Restaino S; Mancini D
J Clin Endocrinol Metab; 2012 Dec; 97(12):4481-90. PubMed ID: 23024190
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
[TBL] [Abstract][Full Text] [Related]
16. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Huang J; Meixner L; Fernandez S; McCutchan JA
AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
19. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
20. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
